Health & Research Goals
Hormone Beast
Bestia Hormonal
Triple Metabolic Receptor Stack
Select a vial or the total
Primary Description
The most advanced incretins agonist combination available. Tirzepatide (dual GLP-1/GIP) plus Retatrutide (triple GLP-1/GIP/Glucagon) provide the most comprehensive incretins receptor system coverage. MOTS-C adds mitochondrial support to optimize energy metabolism.
Demonstrated Effects
- Maximum fat loss via triple receptor metabolic agonism
- Appetite suppression and improved glucose homeostasis
- MOTS-C prevents metabolic adaptation during weight loss
- Hepatic fat mobilization and energy expenditure increase
- Improved insulin sensitivity across three receptor pathways
Proposed Mechanisms of Action
Combined Mechanism
Tirzepatide activates GLP-1 receptors (appetite suppression, insulin secretion) and GIP receptors (adipocyte lipolysis, bone metabolism). Retatrutide adds glucagon receptor agonism, increasing hepatic fat mobilization and basal energy expenditure — triple receptor coverage across the entire metabolic axis. MOTS-C translocates to the nucleus and activates AMPK via the folate cycle, upregulating mitochondrial fatty acid oxidation and preventing the metabolic adaptation that occurs during aggressive caloric restriction.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
The most aggressive metabolic reset protocol in peptide research. Tirzepatide (dual GLP-1/GIP agonist) combined with Retatrutide (triple GLP-1/GIP/glucagon agonist) and MOTS-C (mitochondrial exercise peptide) delivers comprehensive fat loss, appetite suppression, and cellular metabolic activation simultaneously.
Safety Profile
Common Side Effects
- Nausea, vomiting, and diarrhea are common GLP-1 class side effects — start at lowest dose and titrate slowly
- Monitor blood glucose closely if taking antidiabetic medications (hypoglycemia risk)
- Injection site reactions — rotate injection sites
- Risk of pancreatitis — discontinue if severe abdominal pain develops
- Thyroid C-cell tumor risk (GLP-1 class warning) — monitor thyroid function
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia type 2 (MEN2)
- Active or history of pancreatitis
- Type 1 diabetes with insulin dependence
- Pregnancy or breastfeeding
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Bestia Hormonal
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.